Rigel Pharmaceuticals
RIGL
95 hedge funds and large institutions have $300M invested in Rigel Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 12 closing their positions.
108% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $531K
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
1% more funds holding
Funds holding: 94 → 95 (+1)
5% more capital invested
Capital invested by funds: $287M → $300M (+$13.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$8.63M |
| 2 |
Morgan Stanley
New York
|
+$4.91M |
| 3 |
Millennium Management
New York
|
+$3.97M |
| 4 |
BC
Broadfin Capital
New York
|
+$1.88M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.94M |
| 3 |
DM
Deerfield Management
New York
|
-$5.99M |
| 4 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$3.01M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.76M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WB
101
WesBanco Bank
Wheeling,
West Virginia
| – | -$134K | -4,000 | Closed |
|
|
U
102
UBS
Zurich,
Switzerland
| – | -$80.8K | -2,213 | Closed |
|
|
BJ
103
BlackRock Japan
Tokyo,
Japan
| – | -$58K | -1,722 | Closed |
|
104
Nomura Holdings
Tokyo,
Japan
| – | -$39K | -1,162 | Closed |
|
|
WAM
105
Wolverine Asset Management
Chicago,
Illinois
| – | -$9.85K | -270 | Closed |
|
RIGL Hedge Fund Activity: Q3 2013 in Review
95 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2013, worth a combined $300M — up 4.6% from $287M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RIGL positions and 12 closed out — a net gain of 2 holders — while 30 added to existing stakes and 33 trimmed.
The largest buyer was Palo Alto Investors, adding an estimated $8.63M. The largest seller was Wellington Management Group, cutting an estimated $13.8M.
- 95 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2013, up from 94 in Q2 2013.
- Funds reported $300M of Rigel Pharmaceuticals stock for Q3 2013, up 4.6% quarter-over-quarter.
- 14 funds opened new Rigel Pharmaceuticals positions in Q3 2013 and 12 closed out, a net change of +2 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2013 was Palo Alto Investors, an estimated $8.63M added.
- The largest Rigel Pharmaceuticals seller in Q3 2013 was Wellington Management Group, an estimated $13.8M sold.
Based on aggregated 13F filings for Q3 2013.